Aslıhan DOĞRU -TDO- The European Union (EU) will receive an additional 50 million doses of the vaccine developed by BioNTech-Pfizer for the new type of coronavirus (Covid-19) in the second quarter.
The EU has also begun negotiations to receive an additional 1.8 billion doses of BioNTech-Pfizer vaccines.
EU Commission President Ursula von der Leyen made statements in Brussels on the fight against the Covid-19 pandemic and the EU's vaccination strategy.
Von der Leyen stated that the pandemic remains a serious threat and that they are competing against time and that their goal is to quickly vaccinate 70% of the adult population.
"We have reached 100 million vaccinations in the EU. More than 25 percent of these 100 million doses are second-dose vaccines. More than 27 million Europeans have been fully vaccinated. I am pleased to announce that we have reached an agreement with BioNTech-Pfizer to speed up vaccine delivery. BioNTech-Pfizer will deliver 50 million additional doses of vaccines in the second quarter," she said.
Von der Leyen said it was understood that 50 million doses of the vaccine had previously been delivered in the fourth quarter, but that date has now been brought forward and that BioNTech-Pfizer will provide a total of 250 million doses of vaccines to the EU in the second quarter.
"This contract envisions the delivery of 1.8 billion additional doses of vaccines in 2022 and 2023," von der Leyen said, adding that they expect to quickly complete such vaccine purchase negotiations.
On the other hand, it was stated that there may be similar contracts with other companies.